<DOC>
	<DOC>NCT00615563</DOC>
	<brief_summary>The primary objective of this trial was to assess the presence of susceptibility to tipranavir and other ARVs of the HIV-1 isolates in treatment experienced patients. The secondary objective was to examine clinicians' use of HIV drug resistance testing in treatment experienced patients currently failing a PI based HAART regimen.</brief_summary>
	<brief_title>Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion criteria Patients that meet the following inclusion criteria will be eligible for participation in this study: 1. Signed patient informed consent prior to study participation. 2. HIV1 infected male or female ?18 years of age. 3. Have confirmed (2 consecutive) HIV RNA ?1000 copies/mL (one of the results must be within 3 months of enrollment into the study). 4. Current HAART regimen contains a protease inhibitor for ?3 months. 5. Physicians considering a change in the patient?s HAART regimen. f.) History of treatment with 2 or more protease inhibitors (including the current PI). Low dose ritonavir (i.e.&lt; 400 mg. bid) is not counted as one of the PIs. Exclusion criteria A patient with any of the following criteria will be excluded from participation in the study: 1. ARV medication naive. 2. Active opportunistic infection. c.) Known or suspected nonadherence to current HAART regimen as assessed by the investigator.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>